MANUSO JAMES S J

SEC source: 0000905148-26-001787 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 317,318

F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

SEC source: 0000897069-26-000365 · form4.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,240

Underlying: Common Stock · 156,240 shares

Expires 2036-02-12

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

SEC source: 0000905148-26-000036 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 292,951

F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2026. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock the day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $1.99 per share, the average of the high and low price of the common stock, the day prior to the grant date.

SEC source: 0000905148-25-001429 · form4.xml · derivative · entry 2

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,592

Underlying: Common Stock · 79,592 shares

Expires 2035-04-29

F2 · derivative.exercise_date: The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

SEC source: 0000905148-25-001429 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 261,763

F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

SEC source: 0000897069-25-000035 · form4.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,590

Underlying: Common Stock · 59,590 shares

Expires 2035-01-02

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

SEC source: 0000905148-25-000039 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,259

F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2025. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock on the grant date (rounded down to the nearest whole share). The average fair market value was $1.23 per share, the average of the high and low price of the common stock on the date of grant.

SEC source: 0000897069-24-002003 · form4.xml · derivative · entry 2

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,553

Underlying: Common Stock · 13,553 shares

Expires 2034-02-28

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-002003 · form4.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,553

Underlying: Common Stock · 13,553 shares

Expires 2033-01-16

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000905148-24-001712 · form4.xml · derivative · entry 2

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,181

Underlying: Common Stock · 35,181 shares

Expires 2034-06-10

F2 · derivative.exercise_date: The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

SEC source: 0000905148-24-001712 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,037

F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

SEC source: 0001140361-24-000496 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,894

F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2024. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $2.81 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to January 1, 2024.

SEC source: 0001140361-23-029023 · form4.xml · derivative · entry 2

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,639

Underlying: Common Stock · 9,639 shares

Expires 2033-06-05

F2 · derivative.exercise_date: Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

SEC source: 0001140361-23-029023 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,804

F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

SEC source: 0001140361-23-019677 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,828

F1 · price: The Reporting Person was granted shares of common stock in lieu of incremental cash amounts for board services for 2023. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $4.27 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to April 19, 2023.

SEC source: 0001140361-23-001517 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,009

F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2023. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $3.07 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to January 11, 2023.

SEC source: 0001140361-22-036952 · form4.xml · derivative · entry 2

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 787 shares

Expires 2022-10-12

F1 · derivative.expiration_date: The expiration date of the Series B Warrants occurred on the later of (x) the Reservation Date (as defined in the Series B Warrants) and (y) the date on which the Series B Warrants were exercised in full.

SEC source: 0001140361-22-036952 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,465

SEC source: 0001140361-22-025284 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,678

F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for the second half of 2022. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $2.02 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to July 1, 2022.

SEC source: 0001140361-22-023050 · form4.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-12

F1 · derivative.exercise_date: Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

SEC source: 0001140361-22-020364 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,570

SEC source: 0001140361-21-038872 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,570

F1 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were purchased at prices ranging from $3.4966 to $3.4998. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001140361-21-020420 · form4.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-07

F1 · derivative.exercise_date: Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

SEC source: 0001140361-20-026658 · form4.xml · derivative · entry 3

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 787

Underlying: Common Stock · 787 shares

Expires 2022-01-28

F2 · shares: Ssubject to adjustment based on certain price reset provisions.

F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $25,000

SEC source: 0001140361-20-026658 · form4.xml · derivative · entry 2

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,697

Underlying: Common Stock · 6,697 shares

Expires 2025-11-19

F2 · derivative.exercise_price: Ssubject to adjustment based on certain price reset provisions.

F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $25,000

SEC source: 0001140361-20-026658 · form4.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,570

F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $25,000

SEC source: 0001140361-20-025540 · form4.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2030-11-11

F1 · derivative.exercise_date: Vesting in 12 equal monthly increments beginning on November 30, 2020, except for October 31, 2021 when the balance vests.

SEC source: 0001596771-20-000113 · primary_doc.xml · derivative · entry 3

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,825

Underlying: Common Stock · 52,825 shares

Expires 2029-12-27

F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc.

F3 · derivative.exercise_date: 1,479 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2022, subject to continued service.

SEC source: 0001596771-20-000113 · primary_doc.xml · derivative · entry 2

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,663

Underlying: Common Stock · 35,663 shares

Expires 2028-12-20

F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc.

F2 · derivative.exercise_date: The option is fully vested.

SEC source: 0001596771-20-000113 · primary_doc.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,136

F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc.

SEC source: 0001573202-17-000009 · primary_doc.xml · derivative · entry 3

MANUSO JAMES S J · CIK 0001236365 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 608,704

Underlying: Common Stock · 608,704 shares

Expires 2022-12-09

F2 · kind: On December 9, 2017, Dr. Manuso forgave all of the accrued but unpaid compensation to which, pursuant to his employment agreement, he was entitled as of September 30, 2017, an aggregate of $878,360. On that date, the Company granted to Dr. Manuso options to purchase 608,704 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $878,360. These Common Stock Options vested upon issuance.

F2 · price: On December 9, 2017, Dr. Manuso forgave all of the accrued but unpaid compensation to which, pursuant to his employment agreement, he was entitled as of September 30, 2017, an aggregate of $878,360. On that date, the Company granted to Dr. Manuso options to purchase 608,704 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $878,360. These Common Stock Options vested upon issuance.

F2 · derivative.exercise_date: On December 9, 2017, Dr. Manuso forgave all of the accrued but unpaid compensation to which, pursuant to his employment agreement, he was entitled as of September 30, 2017, an aggregate of $878,360. On that date, the Company granted to Dr. Manuso options to purchase 608,704 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $878,360. These Common Stock Options vested upon issuance.

SEC source: 0001573202-17-000009 · primary_doc.xml · derivative · entry 2

MANUSO JAMES S J · CIK 0001236365 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,195

Underlying: Common Stock · 2,195 shares

Expires 2020-09-30

F5 · derivative.exercise_price: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.

F5 · shares: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.

F1 · price: Dr. Manuso purchased shares and warrants in a private transaction for an aggregate of $5,000, or $4.56 per unit, with each unit consisting of one share and warrants to purchase two additional shares of the Company's common stock.

F5 · derivative.underlying_shares: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.

F5 · balance_after: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.

SEC source: 0001573202-17-000009 · primary_doc.xml · nonDerivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,252

F5 · shares: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.

F1 · price: Dr. Manuso purchased shares and warrants in a private transaction for an aggregate of $5,000, or $4.56 per unit, with each unit consisting of one share and warrants to purchase two additional shares of the Company's common stock.

F5 · balance_after: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.

SEC source: 0001573202-17-000001 · primary_doc.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: common stock · 50,000 shares

Expires 2022-06-30

F1 · derivative.exercise_date: These Common Stock Options vested upon issuance.

SEC source: 0001363763-17-000002 · primary_doc.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director · Preident & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2017-01-18

F1 · derivative.exercise_date: These Common Stock Options vest in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017.